Risvutatug Rezetecan Meets Overall Survival Endpoint in Phase III SCLC Trial in China
Jul 14, 2026
View online
Risvutatug Rezetecan Meets Overall Survival Endpoint in Phase III SCLC Trial in China
OMNIVORE Long-Term Follow-Up: Durable Treatment-Free Survival After Early Response to Nivolumab in Advanced RCC
Steven O’Day: BOT+BAL Offers New Hope for MSS Colon Cancer
Ophira Ginsburg: Why ASCO Africa Was a Standout Meeting for Cancer Equity
ADC-Related Interstitial Lung Disease: A Class-Relevant Toxicity That Requires Early Recognition
10 Must-Read Posts in Immuno-Oncology This Week
Sam Neill Dies at 78 After Living With Rare T-Cell Lymphoma
Global Ovarian Cancer Research Consortium AI Accelerator Grant — OCRA
ACOG Foundation 2026 Request for Grant Proposals
HER2 and Colorectal Cancer: What Advocates Need to Know
Breast Cancer Trials 47th Annual Scientific Meeting
The Voice of Oncology
Unsubscribe
|
Manage subscription
OncoDaily, P53 Inc.
867 Boylston Street, 5th Floor, Suite 1094, Boston, MA 02116
Copyright (C) 2023-2026. OncoDaily, P53 Inc. All rights reserved.
